NVCR - NovoCure Ltd

13.04
-1.190   -9.126%

Share volume: 1,368,599
Last Updated: 03-06-2026
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$14.23
-1.19
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 25%
Dept financing 47%
Liquidity 75%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.55%
1 Month
30.01%
3 Months
8.13%
6 Months
3.49%
1 Year
-35.38%
2 Year
-24.58%
Key data
Stock price
$13.04
P/E Ratio 
0.00
DAY RANGE
$13.01 - $13.91
EPS 
-$1.22
52 WEEK RANGE
$9.82 - $21.55
52 WEEK CHANGE
-$35.73
MARKET CAP 
1.448 B
YIELD 
N/A
SHARES OUTSTANDING 
113.794 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
BETA 
2.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,205,151
AVERAGE 30 VOLUME 
$3,297,526
Company detail
CEO: Asaf Danziger
Region: US
Website: novocure.com
Employees: 1,320
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

NovoCure Limited engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma.

Recent news